1. Home
  2. LWLG vs PRTA Comparison

LWLG vs PRTA Comparison

Compare LWLG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightwave Logic Inc.

LWLG

Lightwave Logic Inc.

N/A

Current Price

$7.17

Market Cap

578.6M

Sector

Industrials

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.37

Market Cap

482.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LWLG
PRTA
Founded
1991
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.6M
482.3M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
LWLG
PRTA
Price
$7.17
$9.37
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
1.9M
416.4K
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$95,605.00
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
136.05
N/A
52 Week Low
$0.79
$4.32
52 Week High
$6.26
$14.34

Technical Indicators

Market Signals
Indicator
LWLG
PRTA
Relative Strength Index (RSI) 74.92 50.68
Support Level $3.08 $8.23
Resistance Level N/A $9.59
Average True Range (ATR) 0.58 0.50
MACD 0.20 0.06
Stochastic Oscillator 89.00 50.14

Price Performance

Historical Comparison
LWLG
PRTA

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: